27 April 2022>: Clinical Research
Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma
Lei Wang 1CD* , Lei Wang 23DEF* , Bo Xiao 4BC , Mingxuan Cui 4CDE , Bo Zhang 4A*DOI: 10.12659/MSM.934936
Med Sci Monit 2022; 28:e934936
Table 1 Comparison of tumor markers and hepatobiliary function between 2 groups.
Group | AFP | CA19-9 | ALT | AST | ||||
---|---|---|---|---|---|---|---|---|
S | L | S | L | S | L | S | L | |
Start point | >1000 | >1000 | 129.6±31.6 | 127.1±32.3 | 47.3±7.8 | 51.2±7.8 | 52.2±9.1 | 54.7±7.9 |
1 month | >1000 | >1000 | 118.7±30.3 | 101.5±24.4 | 31.2±5.8 | 26.0±5.7 | 47.4±8.1 | 41.3±6.1 |
3 months | 582.3±91.8 | 395.4±67.2* | 58.7±17.4 | 10.1±3.2* | 30.0±6.6 | 24.1±3.6* | 34.1±6.8 | 27.3±4.3* |
6 months | 60.4±16.8 | 17.9±5.2* | 42.8±8.9 | 5.77±1.6* | 23.4±5.4 | 14.1±3.1* | 31.7±6.9 | 26.5±5.2* |
Start point | 27.8±6.3 | 30.7±6.5 | 12.3±4.2 | 13.1±4.1 | 6017.7±593.8 | 6143.7±896.4 | ||
1 month | 21.2±5.3 | 22.5±7.3 | 9.7±3.1 | 8.1±3.2 | 5713.8±896.3 | 5611.8±916.8 | ||
3 months | 18.8±4.2 | 13.5±2.6* | 7.1±2.1 | 4.7±1.2* | 5412.2±981.7 | 5321.8±897.9 | ||
6 months | 16.8±3.8 | 12.1±3.1* | 6.7±2.5 | 4.3±1.6* | 5198.8±917.4 | 5233.9±898.3 | ||
S indicates sorafenib treatment and L indicates lenvatinib treatment. * Represents AFP – alpha-fetoprotein; CA19-9 – carbohydrate antigen 19-9; ALT – alanine aminotransferase; AST – aspartate aminotransferase; TBIL – total bilirubin; DBIL – direct bilirubin; CHE – cholinesterase. |